India's Piramal To Share With Employees Sale Of Unit To Abbott
This article was originally published in PharmAsia News
Executive SummaryPiramal Healthcare's $3.7 billion sale of its formulations business to U.S.-based Abbott Laboratories means cash bonuses equal to as much as six months of salary for many of Piramal's 8,000 employees in India
You may also be interested in...
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.